NCT02952729View on ClinicalTrials.gov

Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 21, 2016

Primary Completion Date

January 28, 2019

Study Completion Date

January 28, 2019

Conditions
Advanced Breast CancerAdvanced Nonsmall Cell Lung CancerAdvanced Gastric Cancer
Interventions
DRUG

XMT-1522

one intravenous dose administered in-clinic every 21 days

Trial Locations (5)

33607

Moffitt Cancer Center, Tampa

37203

Sarah Cannon Research Institute, Nashville

75230

Mary Crowley Cancer Research Center, Dallas

78229

South Texas Accelerated Research Therapeutics (START), San Antonio

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

Mersana Therapeutics

INDUSTRY

NCT02952729 - Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 | Biotech Hunter | Biotech Hunter